News

We’re consulting on upcoming changes to how the Pharmaceutical Schedule will work. Changes to how the Pharmaceutical Schedule will work  (consultation closes 13 March 2026) New medicine supply notices Pedialyte: Claiming update   Urgent action required: Pharmacies need to check any claims they made for Pedialyte in February 2026. See the website for more details. Ticagrelor (Tab 90 mg)  (Pharmacode: 2638770) The supplier anticipates running out in mid-March. A S29 alternative has been listed...

Please see the AWHC Newsletter attached.

Nurse Practitioner Permanent full-time 0.9-1.0 FTE | Salary $142,470-$157,252 depending on experience The Gardens, Manurewa location, with free parking on site Onsite café with discounted coffee, health insurance, boutique 2 nd edition store and more… At Tōtara Hospice, you’re not just a nurse — you’re a purpose-driven clinician making a real impact every day.   Imagine starting your morning surrounded by native trees, peaceful gardens, and a calm oasis far from the city rush — maybe with a...

We’re seeking NPs for contract roles across the Wellington region to provide weekly rounds to Aged Residential Care (ARC) facilities, delivering high-quality care to older patients with complex needs.   You will work closely with onsite nurses and care teams to: Provide excellent clinical care to ARC residents (rest home level care and above).  Complete regular scheduled visits onsite, with key tasks including new admission assessments, acute care, regular examinations, and medication reviews...

The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 (the Regulations) set the minimum quality standard that medicinal cannabis products and ingredients must meet before they can be supplied in New Zealand. Importers, manufacturers, and suppliers must apply for assessment and provide evidence to the Medicinal Cannabis Agency to verify that their products meet the minimum quality standard. Sunrise T21.1 has been verified as meeting the minimum quality standard. More information on the...

Pharmac is seeking feedback on a proposal to widen access to nivolumab and ipilimumab for people with stage 3B to stage 4 melanoma that can be removed with surgery. If approved, funded access to these medicines would be widened from 1 May 2026. For more information on this consultation, read the full proposal to widen access to nivolumab and ipilimumab for resectable melanoma We welcome your feedback. Consultation is open until 5pm Monday 9 March 2026. Please send your feedback to...